CN1222510C - 苯甲酰基胍盐 - Google Patents

苯甲酰基胍盐 Download PDF

Info

Publication number
CN1222510C
CN1222510C CNB028049926A CN02804992A CN1222510C CN 1222510 C CN1222510 C CN 1222510C CN B028049926 A CNB028049926 A CN B028049926A CN 02804992 A CN02804992 A CN 02804992A CN 1222510 C CN1222510 C CN 1222510C
Authority
CN
China
Prior art keywords
benzoylguanidine
compound
compounds
formula
active substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB028049926A
Other languages
English (en)
Chinese (zh)
Other versions
CN1491213A (zh
Inventor
克里斯琴·艾克迈耶
彼得·西格
沃尔克马·科纳
罗尔夫·赫脱
沃纳·拉尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma GmbH and Co KG filed Critical Boehringer Ingelheim Pharma GmbH and Co KG
Publication of CN1491213A publication Critical patent/CN1491213A/zh
Application granted granted Critical
Publication of CN1222510C publication Critical patent/CN1222510C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Surgery (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNB028049926A 2001-02-15 2002-02-14 苯甲酰基胍盐 Expired - Fee Related CN1222510C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10106970.7 2001-02-15
DE10106970A DE10106970A1 (de) 2001-02-15 2001-02-15 Neues Benzoylguanidinsalz

Publications (2)

Publication Number Publication Date
CN1491213A CN1491213A (zh) 2004-04-21
CN1222510C true CN1222510C (zh) 2005-10-12

Family

ID=7674094

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028049926A Expired - Fee Related CN1222510C (zh) 2001-02-15 2002-02-14 苯甲酰基胍盐

Country Status (31)

Country Link
US (2) US20080025919A1 (enExample)
EP (1) EP1362030B1 (enExample)
JP (3) JP4408626B2 (enExample)
KR (1) KR100862176B1 (enExample)
CN (1) CN1222510C (enExample)
AT (1) ATE553078T1 (enExample)
AU (1) AU2002250939B2 (enExample)
BG (1) BG66330B1 (enExample)
BR (1) BR0207867A (enExample)
CA (1) CA2434829C (enExample)
CY (1) CY1112878T1 (enExample)
CZ (1) CZ303277B6 (enExample)
DE (1) DE10106970A1 (enExample)
DK (1) DK1362030T3 (enExample)
EA (1) EA006245B1 (enExample)
EC (1) ECSP034708A (enExample)
EE (1) EE200300393A (enExample)
ES (1) ES2385472T3 (enExample)
HR (1) HRP20030653B1 (enExample)
HU (1) HU230035B1 (enExample)
IL (1) IL156934A (enExample)
NO (1) NO20033299D0 (enExample)
NZ (1) NZ528081A (enExample)
PL (1) PL213300B1 (enExample)
PT (1) PT1362030E (enExample)
RS (1) RS52014B (enExample)
SI (1) SI1362030T1 (enExample)
SK (1) SK287830B6 (enExample)
UA (1) UA74625C2 (enExample)
WO (1) WO2002064563A1 (enExample)
ZA (1) ZA200305365B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10106970A1 (de) * 2001-02-15 2002-08-29 Boehringer Ingelheim Pharma Neues Benzoylguanidinsalz
US6982256B2 (en) 2001-09-07 2006-01-03 Boehringer Ingelheim Pharma Kg Tolerance of 4-(4-(2-pyrrolylcarbonyl)-1-piperazinyl)-3-trifluoromethyl-benzoylguanidine in intravenous administration
DE10144030A1 (de) * 2001-09-07 2003-03-27 Boehringer Ingelheim Pharma Verbesserung der lokalen Verträglichkeit bei intravenöser Verabreichung von 4-(4-(2-Pyrrolylcarbonyl-1-piperazinyl)-3-trifluormethyl-benzoylguanidin
US20110118262A1 (en) * 2008-07-08 2011-05-19 Boehringer Ingelheim International Gmbh Pyrrolidinyl and Piperidinyl Compounds Useful as NHE-1 Inhibitiors
US10405746B2 (en) * 2014-04-14 2019-09-10 The University Of Memphis Research Foundation Wireless analog passive sensors
US12369831B1 (en) 2018-04-30 2025-07-29 Bashir I. Morshed Apparatus and method to capture body signals with conjugate coils and paired coils

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19601303A1 (de) * 1996-01-16 1997-07-17 Boehringer Ingelheim Kg Neuartige Benzoylguanidin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung bei der Herstellung von Arzneimitteln
DE19843489B4 (de) * 1998-09-22 2006-12-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Benzoylguanidin-Abkömmlinge mit vorteilhaften Eigenschaften, Verfahren zu ihrer Herstellung und ihre Verwendung bei der Herstellung von Arzneimitteln, sowie diese enthaltende pharmazeutische Zubereitung
US6323207B1 (en) * 1998-09-22 2001-11-27 Boehringer Ingelheim Pharma Kg Benzoylguanidine derivatives
US6730678B2 (en) * 2001-02-15 2004-05-04 Boehringer Ingelheim Pharma Kg Benzoylguanidine salt and hydrates thereof
DE10106970A1 (de) * 2001-02-15 2002-08-29 Boehringer Ingelheim Pharma Neues Benzoylguanidinsalz

Also Published As

Publication number Publication date
PL362129A1 (en) 2004-10-18
HU230035B1 (hu) 2015-05-28
BG108065A (bg) 2005-01-31
KR100862176B1 (ko) 2008-10-09
IL156934A (en) 2005-12-18
SK10202003A3 (sk) 2004-02-03
ES2385472T3 (es) 2012-07-25
YU61503A (sh) 2006-05-25
HRP20030653B1 (en) 2012-06-30
HRP20030653A2 (en) 2005-06-30
JP2009235097A (ja) 2009-10-15
EA006245B1 (ru) 2005-10-27
KR20030075197A (ko) 2003-09-22
CA2434829A1 (en) 2002-08-22
DK1362030T3 (da) 2012-07-09
JP4408626B2 (ja) 2010-02-03
PT1362030E (pt) 2012-07-04
AU2002250939B2 (en) 2007-09-06
EP1362030A1 (de) 2003-11-19
EA200300771A1 (ru) 2004-02-26
CN1491213A (zh) 2004-04-21
HUP0303027A2 (hu) 2003-12-29
BR0207867A (pt) 2004-03-23
NZ528081A (en) 2005-10-28
NO20033299L (no) 2003-07-22
JP5745215B2 (ja) 2015-07-08
PL213300B1 (pl) 2013-02-28
RS52014B (sr) 2012-04-30
SI1362030T1 (sl) 2012-07-31
SK287830B6 (sk) 2011-11-04
CY1112878T1 (el) 2016-04-13
BG66330B1 (bg) 2013-06-28
EE200300393A (et) 2003-12-15
US20080025919A1 (en) 2008-01-31
IL156934A0 (en) 2004-02-08
DE10106970A1 (de) 2002-08-29
CA2434829C (en) 2009-12-08
ATE553078T1 (de) 2012-04-15
CZ20032210A3 (cs) 2003-12-17
JP2013107906A (ja) 2013-06-06
US20080241077A1 (en) 2008-10-02
JP2004518721A (ja) 2004-06-24
HK1064093A1 (zh) 2005-01-21
NO20033299D0 (no) 2003-07-22
WO2002064563A1 (de) 2002-08-22
UA74625C2 (en) 2006-01-16
ZA200305365B (en) 2004-04-22
ECSP034708A (es) 2003-12-24
EP1362030B1 (de) 2012-04-11
HUP0303027A3 (en) 2010-04-28
CZ303277B6 (cs) 2012-07-11

Similar Documents

Publication Publication Date Title
JP2022176961A (ja) ｛［５－（３－クロロフェニル）－３－ヒドロキシピリジン－２－カルボニル］アミノ｝酢酸の固体形態、組成物、及びその使用
CN101535311B (zh) 吡咯并嘧啶酮衍生物的盐及其制备方法
JP5745215B2 (ja) 新規ベンゾイルグアニジン塩
KR20220004083A (ko) (e)-3-[2-(2-티에닐)비닐]-1h-피라졸의 고체 형태
CN101296921A (zh) S-奥美拉唑锶或其水合物，它们的制备方法，和包含它们的药物组合物
US6730678B2 (en) Benzoylguanidine salt and hydrates thereof
WO2010111951A1 (zh) 普拉格雷氢溴酸盐的晶体
KR102544543B1 (ko) L,d-엘도스테인의 개별적 공결정화물
JP5530369B2 (ja) 新規な結晶形
CN104768927B (zh) (3s,3s’)‑4,4’‑二硫烷二基双(3‑氨基丁烷‑1‑磺酸)合l‑赖氨酸的新的结晶相
HK1064093B (en) Benzoylguanidine salt
JP5017274B2 (ja) Ｓ−オメプラゾールストロンチウム塩またはその水和物、その製造方法、及びこれを含む医薬組成物
MXPA03007192A (en) Novel benzoylguanidine salt

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1064093

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20051012

Termination date: 20170214